A Randomized, Double-masked, Multicenter, Laser Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema
Latest Information Update: 25 Feb 2014
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms REVEAL
- Sponsors Novartis
- 25 Feb 2014 New trial record
- 21 Feb 2014 Lucentis [ranibizumab] was approved by Japanese regulatory bodies for the treatment of diabetic macular oedema based on results from the REVEAL trial, according to a Novartis media release.